{"entity":{"id":"nct01890746","kind":"trial","name":"A Safety and Efficacy Study of Eltrombopag in Subjects With AML","aka":[],"tldr":"A phase 2 trial of Daunorubicin, Cytarabine and Eltrombopag in Leukaemia, run by Novartis Pharmaceuticals, completed.","summary":"A Safety and Efficacy Study of Eltrombopag in Subjects With AML is a phase 2 interventional study registered as NCT01890746 by Novartis Pharmaceuticals, with 148 participants recorded, started 2013-09-05 and reaching its primary completion in 2015-03-13. Interventions recorded: Daunorubicin, Cytarabine, Eltrombopag, Placebo. Conditions recorded: Acute Leukaemia.\n\nLinked to the drug Eltrombopag because the registry names it among its interventions and Leukaemia among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT01890746","url":"https://clinicaltrials.gov/study/NCT01890746"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["leukaemia"],"sections":[],"technologies":[],"targets":[],"drugs":["daunorubicin","cytarabine","eltrombopag"],"companies":["novartis"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT01890746","phase":"2","setting":"A Randomized, Blinded, Placebo-Controlled, Dose Finding Study to Assess the Safety and Efficacy of the Oral Thrombopoietin Receptor Agonist, Eltrombopag, Administered to Subjects With Acute Myelogenous Leukaemia (AML) Receiving Induction Chemotherapy","sponsor":"Novartis Pharmaceuticals","started":"2013-09-05","startedType":"actual","yearReported":2016,"enrolled":148,"enrolledBasis":"registry","outcomes":[{"endpoint":"Number of Participants With Liver Events.","primary":true,"unit":"participants","arms":[{"name":"Eltrombopag (ELQ) QD","n":74,"value":2,"note":"Figures from the ClinicalTrials.gov results section (first posted 2016-06-14), not from a publication"},{"name":"Placebo QD","n":71,"value":6}],"source":"https://clinicaltrials.gov/study/NCT01890746?tab=results"},{"endpoint":"Overall Survival (OS)","unit":"participants","arms":[{"name":"Eltrombopag (ELQ) QD","n":74,"value":39,"note":"Figures from the ClinicalTrials.gov results section (first posted 2016-06-14), not from a publication"},{"name":"Placebo QD","n":74,"value":30}],"hr":1.54,"ci":[0.96,2.47],"p":"0.0688","source":"https://clinicaltrials.gov/study/NCT01890746?tab=results"}]},"route":"/trials/nct01890746/","neighbours":{"cancer":[{"id":"leukaemia","kind":"cancer","name":"Leukaemia (all types)","route":"/cancers/leukaemia/"}],"drug":[{"id":"cytarabine","kind":"drug","name":"Cytarabine","route":"/drugs/cytarabine/"},{"id":"daunorubicin","kind":"drug","name":"Daunorubicin","route":"/drugs/daunorubicin/"},{"id":"eltrombopag","kind":"drug","name":"Eltrombopag","route":"/drugs/eltrombopag/"}],"company":[{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/"}]}}